Pancreatic Cancer Research

ResearcherNorthwell HealthActive in the last 2 years

Craig Devoe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2290-1884; OpenAlex author ID A5073040359. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
54
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 3 papers · 2026: 1 paper

Papers 7

  1. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Co-author DOI 10.1038/s41591-026-04734-7↗
  2. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Panc… Co-author DOI 10.1200/jco-25-00436↗
  3. Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metast… Co-author DOI 10.1200/jco-25-02195↗
  4. Management of Peritoneal Metastasis in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/curroncol32020103↗
  5. Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer. Co-author DOI 10.17140/poj-3-e010↗
  6. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-18-0349↗
  7. Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-15-2010↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel A. King · 3 shared papers, 2025 · strength 0.56
  2. Harshabad Singh · 3 shared papers, 2025–2026 · strength 0.52
  3. Eileen Mary O'Reilly · 3 shared papers, 2025–2026 · strength 0.52
  4. Sandra Elisabeth Fischer · 2 shared papers, 2025 · strength 0.33
  5. Kai Duan · 2 shared papers, 2025 · strength 0.33
  6. Fieke E. M. Froeling · 2 shared papers, 2025 · strength 0.33
  7. Robert C. Grant · 2 shared papers, 2025 · strength 0.33
  8. Raymond Jang · 2 shared papers, 2025 · strength 0.33
  9. Grainne Mary O'Kane · 2 shared papers, 2025 · strength 0.33
  10. Andrew J. Aguirre · 2 shared papers, 2025 · strength 0.33
  11. Jennifer Jane Knox · 2 shared papers, 2025 · strength 0.33
  12. Elizabeth M. Jaffee · 2 shared papers, 2025 · strength 0.33
  13. Brian Matthew Wolpin · 2 shared papers, 2025 · strength 0.33
  14. Steve Gallinger · 2 shared papers, 2025 · strength 0.33
  15. Daniel John Renouf · 2 shared papers, 2025 · strength 0.33
  16. Erica S. Tsang · 2 shared papers, 2025 · strength 0.33
  17. Kimberly J. Perez · 2 shared papers, 2025 · strength 0.33
  18. Michael Jon Pishvaian · 2 shared papers, 2025 · strength 0.33
  19. Faiyaz Notta · 2 shared papers, 2025 · strength 0.33
  20. David Arthur Tuveson · 2 shared papers, 2025 · strength 0.33
  21. Kenneth H. Yu · 2 shared papers, 2025 · strength 0.33
  22. Daniel A. Laheru · 2 shared papers, 2025 · strength 0.33
  23. Muhammad Wasif Saif · 2 shared papers, 2019–2025 · strength 0.30
  24. Danielle K. DePeralta · 1 shared paper, 2025 · strength 0.24
  25. Sepideh Gholami · 1 shared paper, 2025 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.